Another trial, CheckMate 548, evaluating nivolumab with or without radiation therapy and TMZ in O6-methylguanine-DNA methyltransferase (MGMT)-methylated recurrent GBM patients, also failed to show improved median OS [16]. Here, MGMT is linked to glioblastoma.